These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17525484)

  • 1. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas.
    Giordano TJ
    Endocr Pathol; 2006; 17(4):355-63. PubMed ID: 17525484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling in adrenocortical neoplasia.
    Assie G; Giordano TJ; Bertherat J
    Mol Cell Endocrinol; 2012 Mar; 351(1):111-7. PubMed ID: 22056416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
    Wang C; Sun Y; Wu H; Zhao D; Chen J
    Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular markers and the pathogenesis of adrenocortical cancer.
    Soon PS; McDonald KL; Robinson BG; Sidhu SB
    Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Diagnostic Approach to Adrenocortical Tumors.
    Hodgson A; Pakbaz S; Mete O
    Surg Pathol Clin; 2019 Dec; 12(4):967-995. PubMed ID: 31672302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nestin as a marker in the classification of adrenocortical tumors.
    Lachenmayer A; Lichtenauer UD; Cox T; Schott M; Malendowicz LK; Goretzki PE; Cupisti K; Scherbaum WA; Bornstein SR; Willenberg HS
    Horm Metab Res; 2009 May; 41(5):397-401. PubMed ID: 19294612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
    Blanes A; Diaz-Cano SJ
    Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discerning malignancy in resected adrenocortical neoplasms.
    Sasano H; Suzuki T; Moriya T
    Endocr Pathol; 2001; 12(4):397-406. PubMed ID: 11914473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms.
    Erickson LA; Jin L; Sebo TJ; Lohse C; Pankratz VS; Kendrick ML; van Heerden JA; Thompson GB; Grant CS; Lloyd RV
    Endocr Pathol; 2001; 12(4):429-35. PubMed ID: 11949624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adrenocortical tumors with neuroendocrine differentiation].
    Kazantseva IA; Poliakova GA; Gurevich LG; Morozov IA; Bezuglova TV; Smirnov VB
    Arkh Patol; 2002; 64(5):8-13. PubMed ID: 12575533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
    Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
    J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
    Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
    Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
    Szajerka A; Dziegiel P; Szajerka T; Zabel M; Winowski J; Grzebieniak Z
    Anticancer Res; 2008; 28(5B):2959-65. PubMed ID: 19031940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenocortical carcinoma: review and update.
    Erickson LA; Rivera M; Zhang J
    Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms.
    Enriquez ML; Lal P; Ziober A; Wang L; Tomaszewski JE; Bing Z
    Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):141-5. PubMed ID: 22553814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of aromatase and estrogen receptors in human adrenocortical tumors.
    Barzon L; Masi G; Pacenti M; Trevisan M; Fallo F; Remo A; Martignoni G; Montanaro D; Pezzi V; Palù G
    Virchows Arch; 2008 Feb; 452(2):181-91. PubMed ID: 18157729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxoid adrenocortical neoplasms: a study of the clinicopathologic features and EGFR gene status of ten Chinese cases.
    Zhang J; Sun J; Liang Z; Gao J; Zeng X; Liu T
    Am J Clin Pathol; 2011 Nov; 136(5):783-92. PubMed ID: 22031318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.